Jump Financial LLC Acquires Shares of 15,843 Health Catalyst, Inc. (NASDAQ:HCAT)

Jump Financial LLC acquired a new stake in Health Catalyst, Inc. (NASDAQ:HCAT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,843 shares of the company’s stock, valued at approximately $112,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of HCAT. Kennedy Capital Management LLC raised its stake in Health Catalyst by 42.7% in the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company’s stock valued at $13,369,000 after buying an additional 565,445 shares during the period. Palogic Value Management L.P. acquired a new position in shares of Health Catalyst in the fourth quarter valued at approximately $2,262,000. Raymond James Financial Inc. acquired a new position in shares of Health Catalyst in the fourth quarter valued at approximately $2,044,000. Martin & Co. Inc. TN grew its position in shares of Health Catalyst by 80.0% in the fourth quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company’s stock valued at $3,471,000 after purchasing an additional 218,293 shares during the last quarter. Finally, Impax Asset Management Group plc grew its position in shares of Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after purchasing an additional 195,525 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $4.06 on Tuesday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $285.06 million, a PE ratio of -3.01 and a beta of 1.43. Health Catalyst, Inc. has a twelve month low of $3.56 and a twelve month high of $9.24. The stock’s 50-day simple moving average is $4.27 and its 200 day simple moving average is $6.18.

Analyst Ratings Changes

HCAT has been the topic of several research reports. Citigroup decreased their target price on Health Catalyst from $7.00 to $6.50 and set a “buy” rating on the stock in a research report on Friday. Royal Bank of Canada decreased their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Evercore ISI downgraded Health Catalyst from an “outperform” rating to an “inline” rating in a research report on Wednesday, April 9th. Canaccord Genuity Group reduced their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Finally, KeyCorp reduced their price target on Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and an average price target of $8.05.

Insiders Place Their Bets

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares of the company’s stock, valued at approximately $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Daniel Lesueur sold 16,902 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at approximately $977,450. The trade was a 7.25 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,588 shares of company stock valued at $225,906. 2.50% of the stock is currently owned by corporate insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.